Synergy Chc Corp SEC Filings

Jaime Fickett, identified as Chief Financial Officer of Synergy CHC Corp. (SNYR), reported a grant of a stock option on 09/18/2025. The option covers 150,000 shares of common stock with an exercise price of $2.38 per share and an expiration date shown as 09/18/2030. The filing states the full award is held directly by the reporting person following the transaction. The option vests one-third on the first anniversary of the grant and the remaining two-thirds in equal monthly installments over the subsequent 24 months, subject to continued service. The form was signed by an attorney-in-fact on 09/22/2025.

Synergy CHC Corp. (SNYR) reported a Form 4 showing a stock option grant to Kenek Brands Inc., which is controlled by reporting person Jack Ross, the company's CEO and Chairman. The derivative award is a 750,000-share option with an exercise price of $2.38, recorded on 09/18/2025. The filing states the option vests one-third on the first anniversary of grant and the remaining two-thirds in equal monthly installments over the following 24 months, subject to continued service. The reporting person disclaims direct ownership; the shares are owned directly by Kenek Brands Inc., making Ross an indirect beneficial owner. The Form is signed by counsel on 09/22/2025.

Synergy CHC Corp. ("Synergy" or "SNYR") is offering 1,750,000 shares of common stock with associated underwriter warrants and an overallotment option. For the six months ended June 30, 2025, net revenue was $16.3 million, down 6% versus the prior-year period; FOCUSfactor comprised ~86% of revenue while Flat Tummy was ~14%. For the same period Synergy reported net income of $2.3 million and EBITDA of $5.8 million, representing year-over-year changes of +90% and +67%, respectively. Historic FOCUSfactor annual revenue declined from $37.2 million (2023) to $30.8 million (2024). As of June 30, 2025 the company had a working capital surplus of $12.4 million and an as‑adjusted net tangible book value per share after the offering of $(0.71), producing stated immediate dilution to new investors of $3.21 per share.

Synergy CHC Corp. (SNYR) filed an S-1 registration/prospectus describing a proposed public offering and continuing operations centered on two consumer health brands, FOCUSfactor and Flat Tummy. FOCUSfactor accounted for the majority of revenue (86% for the six months ended June 30, 2025; 88% for year ended December 31, 2024) and generated net revenues of $14.0 million for the six months ended June 30, 2025 and $30.7 million for the year ended December 31, 2024 (down from $37.2 million in 2023). For the six months ended June 30, 2025 the company reported net revenues of $16.3 million, net income of $2.3 million, EBITDA of $5.8 million and a working capital surplus of $12.4 million. The prospectus discloses an assumed public offering price of $3.92 per share, a 7% underwriting commission, and Underwriter Warrants exercisable at $4.31 (110% of the assumed price) with staged expirations over three to five years. The company details international expansion plans, manufacturing and distribution arrangements with major retailers, outstanding indebtedness arrangements and potential dilution metrics showing as-adjusted net tangible book value per share would remain negative under the assumed offering.

Synergy CHC Corp. (SNYR) delivered higher profitability in the second quarter of 2025 while executing material debt refinancing. Revenue for the three months ended June 30, 2025 totaled $8,134,996, including $1,400,000 of license revenue, producing gross profit of $6,238,605. Net income after tax was $1,473,237 for the quarter ($2,349,501 for the six months), driving basic and diluted EPS of $0.17 for the quarter and $0.27 for the six months. Total assets were $19,726,346 with cash and restricted cash of $1,558,561. Total liabilities were $32,105,546, and stockholders' deficit improved to $(12,379,200). In May 2025 the company drew a $17.5 million term loan (with a $2.5 million delayed draw) and used proceeds to repay and restructure prior indebtedness, record a $2,154,522 gain on settlement of notes payable, issue pre-funded warrants and shares in partial debt settlements, and record related debt discounts and issuance costs. Management reported a working capital surplus of $12,383,132 and concluded these actions alleviate substantial doubt about the company’s ability to continue as a going concern for the next twelve months.